Reviewer's report
Title:Medication adherence and persistence in the treatment of Canadian
ulcerative colitis patients: analyses with the RAMQ database
Version: 2Date:25 September 2012
Reviewer: Barney Hawthorne
Reviewer's report:
This is a well-written study of adherence to mesalamine in a large population of
UC patients.
The low adherence and persistence are perhaps unsurprising.
Minor comments
1) No data on dose used, and dose frequency. This data may not be available
from the database. If not this should be made clear.
2) In the background, p.4 2nd paragraph the authors state that Mezavant
multimatrix pH-dependent and gastro-resistant coating is the reason the drug can
be taken once daily. It should be made clear that the Eudragit-S coating delays
release until the distal ileum/caecum is reached, and the hydrophilic and
lipophilic matrix core allows gradual release of drug as it passes through the
colon. The design is intended to allow more mucosal contact with the native drug
before N-acetylation, The manufacturers had the foresight to use trial designs to
demonstrate once-daily therapy was as effective as divided dose, and the same
has now been shown for most other delayed release mesalamine preparations.
This should be clarified.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests
Reviewer's report
Title:Medication adherence and persistence in the treatment of Canadian
ulcerative colitis patients: analyses with the RAMQ database
Version: 2Date:25 September 2012
Reviewer: Barney Hawthorne
Reviewer's report:
This is a well-written study of adherence to mesalamine in a large population of
UC patients.
The low adherence and persistence are perhaps unsurprising.
Minor comments
1) No data on dose used, and dose frequency. This data may not be available
from the database. If not this should be made clear.
2) In the background, p.4 2nd paragraph the authors state that Mezavant
multimatrix pH-dependent and gastro-resistant coating is the reason the drug can
be taken once daily. It should be made clear that the Eudragit-S coating delays
release until the distal ileum/caecum is reached, and the hydrophilic and
lipophilic matrix core allows gradual release of drug as it passes through the
colon. The design is intended to allow more mucosal contact with the native drug
before N-acetylation, The manufacturers had the foresight to use trial designs to
demonstrate once-daily therapy was as effective as divided dose, and the same
has now been shown for most other delayed release mesalamine preparations.
This should be clarified.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests
Please review this paper.
user
Reviewer's report
Title:Medication adherence and persistence in the treatment of Canadian
ulcerative colitis patients: analyses with the RAMQ database
Version: 2Date:25 September 2012
Reviewer: Barney Hawthorne
Reviewer's report:
This is a well-written study of adherence to mesalamine in a large population of
UC patients.
The low adherence and persistence are perhaps unsurprising.
Minor comments
1) No data on dose used, and dose frequency. This data may not be available
from the database. If not this should be made clear.
2) In the background, p.4 2nd paragraph the authors state that Mezavant
multimatrix pH-dependent and gastro-resistant coating is the reason the drug can
be taken once daily. It should be made clear that the Eudragit-S coating delays
release until the distal ileum/caecum is reached, and the hydrophilic and
lipophilic matrix core allows gradual release of drug as it passes through the
colon. The design is intended to allow more mucosal contact with the native drug
before N-acetylation, The manufacturers had the foresight to use trial designs to
demonstrate once-daily therapy was as effective as divided dose, and the same
has now been shown for most other delayed release mesalamine preparations.
This should be clarified.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests
assistant